Daniel Feikin News Today

Advisers to the U.S. Food and Drug Administration on Thursday backed the safety and effectiveness of Pfizer Inc's experimental respiratory syncytial virus (RSV) vaccine, boosting its chances of becoming the first available maternal shot to protect babies from the illness.

The FDA, which typically follows the independent committee's recommendations, is scheduled to decide on approval of the vaccines by May.

Federal health advisers on Tuesday narrowly backed an experimental vaccine from Pfizer that could soon become the first shot to protect older adults against the respiratory illness known as RSV.

Federal health advisers on Tuesday narrowly backed an experimental vaccine from Pfizer that could soon become the first shot to protect older adults

Federal health advisers have narrowly backed an experimental vaccine from Pfizer that could become the first shot to protect older adults against the respiratory illness known as RSV. A panel of Food and Drug Administration advisers voted 7-4 in favor of the shot's safety and effectiveness for people 60 and older. The recommendation is non-binding and the FDA will make its own decision on the vaccine. For most healthy people, RSV is a cold-like nuisance. But the virus can be dangerous for y...

CBS 58 is your local source for the Milwaukee news, Milwaukee weather, and Milwaukee sports.

WASHINGTON (AP) — Federal health advisers on Tuesday narrowly backed an experimental vaccine from Pfizer that could soon become the first shot to protect older adults against the respiratory illness known as RSV.

A panel for the Food and Drug Administration (FDA) has voted that the RSV shots are safe and effective in preventing disease caused by RSV in the over-60s.

A panel of outside advisers to the U.S. Food and Drug Administration (FDA) voted to endorse a vaccine ...

The FDA, which typically follows the independent committee's recommendations, is scheduled to decide on approval of the vaccines by May.